Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Ceftobiprole is approved in Europe for treatment of community-acquired pneumonia and non-ventilator-associated hospital-acquired pneumonia (HAP) in adults. Real-world data are limited.
Methods: This multi-centre, observational, ambispective investigator-initiated study was undertaken in Italy from January 2018 to December 2019 in order to evaluate the use of ceftobiprole in a real-world setting.
Results: Overall, 195 patients from 10 centres were evaluated (68% retrospectively). Male sex was prevalent (n=121, 62%). Median age was 67 [interquartile range (IQR) 53-75] years. Median Charlson Comorbidity Index score was 5 (IQR 3-7). The most common indication was pneumonia (151/195, 77%), especially HAP. Other uses were skin and soft tissue infections (5%), endocarditis (4%) and bone infections (4%). Ceftobiprole was usually an empiric choice (65%), in combination with other drugs (66%) and as second-line therapy (58%). A causative agent was found in 39% of cases. A diagnosis of sepsis was made in 59 cases (30%). Success in the clinically evaluable population (excluding 12 cases due to isolation of pathogens outside ceftobiprole's spectrum of activity) was obtained in 79% of cases, with all-cause mortality of 20%. On multi-level analysis, three predictors were positively associated with clinical success: male gender, pneumonia and detection of causal agent. Sepsis was a negative predictor. Nine factors were independently associated, favourably or unfavourably, with fatal outcome.
Conclusions: Ceftobiprole is a safe and effective therapeutic choice, even in a real-world setting. More data are needed to establish its efficacy in patients with sepsis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijantimicag.2023.106817 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of MDR/XDR severe infections in the critically ill.
Curr Opin Crit Care
October 2025
ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Purpose Of Review: This review aims to summarize current recommendations for the management of serious infections, such as bloodstream infections (BSIs) and ventilator-associated pneumonia, caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens, focusing on evidence from randomized controlled trials (RCTs) and emerging treatment options.
Recent Findings: Vancomycin, linezolid, and daptomycin represent the main therapeutic options for the management of methicillin-resistant Staphylococcus aureus infections; among newer agents, ceftobiprole has recently gained approval for BSI treatment. For vancomycin-resistant Enterococcus faecium BSIs, linezolid and daptomycin remain commonly employed despite the lack of comparative RCTs guiding treatment decisions.
[Beta-lactams and beta-lactamase inhibitors-current developments].
Inn Med (Heidelb)
August 2025
Institut für medizinische Mikrobiologie, Universität Bochum, Bochum, Deutschland.
Numerous new developments in antibacterial substances have been observed in recent years. Most of these are further developments of existing classes, especially beta-lactams, including beta-lactamase inhibitors. These included MRSA-active cephalosporins (ceftaroline and ceftobiprole), new, broadly effective combinations of beta-lactams with beta-lactamase inhibitors, and cefiderocol, a new siderophore cephalosporin that uses the bacteria's own iron uptake systems of gram-negative bacteria to better reach the site of action through the outer membrane.
View Article and Find Full Text PDFCharacterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007-23).
J Antimicrob Chemother
August 2025
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada R3E 0J9.
Objectives: This study reviewed the patient demographic parameters, molecular characteristics and in vitro antimicrobial susceptibility testing results for MRSA isolates infecting inpatients and outpatients presenting for care to tertiary-care Canadian hospitals between 2007 and 2023.
Methods: DNA sequencing was used to generate spa types. Panton-Valentine leukocidin (PVL) genes were detected by PCR.
Gram-positive pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).
J Antimicrob Chemother
August 2025
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9, Canada.
Objectives: CANWARD is a Canadian Antimicrobial Resistance Alliance (CARA)/Health Canada partnered national surveillance study established in 2007 to annually assess antimicrobial susceptibilities for bacterial pathogens isolated from patients receiving care in Canadian hospitals. This paper focuses on Gram-positive pathogens.
Methods: In total, 25 897 Gram-positive pathogens were received and 22 132 underwent CLSI broth microdilution testing providing susceptibility data.
Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia.
J Antimicrob Chemother
August 2025
Pharmacokinetics and Clinical Pharmacy Laboratory, University of Bordeaux Bordeaux 33000, France.
Background: Optimal antimicrobial drug exposure in the lung is required for ensuring successful treatment of community-acquired pneumonia (CAP). Little is known about the intrapulmonary pharmacokinetics (PK) of ceftobiprole when administered by continuous infusion (CI).
Objective: To determine the PK of high doses (3 g/day) CI of ceftobiprole in the plasma and epithelial lining fluid (ELF) in mechanically ventilated patients with CAP.